OpenNashEarnings

Veeva Systems (VEEV) · Software

Veeva Systems Q2 FY2027 earnings: summary, key numbers & outlook

Results filed 26 Aug 2026 · Quarter ended 31 Jul 2026

Slides (17 pages)Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Veeva's Vault CRM had its best quarter ever, with 12 top 20 biopharma commitments, while Veeva Falcon agentic AI for clinical, regulatory and safety moves toward first go-lives.

Veeva's push into AI-driven applications gained traction. Vault CRM has more than 180 customers live, including five top 20 biopharmas, and a top 20 biopharma rolled out Vault CRM with the Agentic Call Report to its full U.S. field team. Development Cloud and Quality Cloud saw broad adoption: a large biopharma selected Veeva EDC, Veeva Safety passed 100 customers, and Quality added more than 30 new customers. Veeva also acquired Copli and launched Veeva Falcon MLR.

Management is steering toward agentic labor: Veeva Falcon has five early adopters and is on track for initial go-lives this year, alongside new standard agents in Vault AI. The main tension is execution. Falcon is a new product that must be readied and proven with early adopters, while Veeva's services business is growing faster than subscriptions as customers adopt new products. Headcount is up 11% year over year.

No call transcript for this quarter, so this summary also draws on: Benzinga (republished on Webull) ↗.

Slides & documents

Open the slide deck (PDF, 17 pages) ↗

Veeva Systems Q2 FY2027 slide deck, page 1Veeva Systems Q2 FY2027 slide deck, page 2Veeva Systems Q2 FY2027 slide deck, page 3Veeva Systems Q2 FY2027 slide deck, page 4Veeva Systems Q2 FY2027 slide deck, page 5Veeva Systems Q2 FY2027 slide deck, page 6

Showing the first 6 of 17 pages.

From Veeva Systems investor relations

SEC filing

Key numbers

Total revenues · GAAP
$928.0 million

up 18% year over year

Net income · GAAP
$273.4 million

up 37% year over year

Diluted EPS · GAAP
$1.66

up from $1.19 one year ago

Non-GAAP diluted EPS · non-GAAP
$2.35

up from $1.99 one year ago

Operating income · GAAP
$275.0 million

up 40% year over year

Non-GAAP operating income · non-GAAP
$415.9 million

up 18% year over year

Gross margin · GAAP
75.0%

from 75.3% a year ago

Operating margin · GAAP
29.6%

from 24.8% a year ago

Segment or metricValueChange
Subscription revenues$766.8 millionup 16% year over year
Commercial Solutions subscription$347.4Mfrom $307,523 a year ago
R&D and Quality Solutions subscription$419.4Mfrom $351,660 a year ago
Professional services and other$161.2Mfrom $129,898 a year ago
Vault CRM customers livemore than 180
Veeva Safety customers100 total customers
Where each number comes from
  • Total revenues: “Total revenues for the second quarter were $928.0 million, up from $789.1 million one year ago, an increase of 18% year over year.”
  • Net income: “Second quarter net income was $273.4 million, compared to $200.3 million one year ago, an increase of 37% year over year.”
  • Diluted EPS: “For the second quarter, fully diluted net income per share was $1.66, compared to $1.19 one year ago, while non-GAAP fully diluted net income per share was $2.35, compared to $1.99 one year ago.”
  • Non-GAAP diluted EPS: “For the second quarter, fully diluted net income per share was $1.66, compared to $1.19 one year ago, while non-GAAP fully diluted net income per share was $2.35, compared to $1.99 one year ago.”
  • Operating income: “Second quarter operating income was $275.0 million, compared to $195.9 million one year ago, an increase of 40% year over year.”
  • Non-GAAP operating income: “Non-GAAP operating income for the second quarter was $415.9 million, compared to $352.6 million one year ago, an increase of 18% year over year.”
  • Gross margin: “Gross margin on total revenues on a GAAP basis | 75.0% | 75.3% | 75.0% | 76.2%”
  • Operating margin: “Operating margin on a GAAP basis | 29.6% | 24.8% | 30.3% | 27.8%”
  • Subscription revenues: “Subscription revenues for the second quarter were $766.8 million, up from $659.2 million one year ago, an increase of 16% year over year.”
  • Commercial Solutions subscription: “Veeva Commercial Solutions | $347,389 | $307,523 | $685,255 | $612,934”
  • R&D and Quality Solutions subscription: “Veeva R&D and Quality Solutions | 419,375 | 351,660 | 811,684 | 681,017”
  • Professional services and other: “Total professional services and other | $161,199 | $129,898 | $313,972 | $254,173”
  • Vault CRM customers live: “Vault CRM leadership grew with more than 180 customers live, including five top 20 biopharmas.”
  • Veeva Safety customers: “Veeva Safety surpassed 100 total customers while securing its second top 20 biopharma win for Safety Workbench.”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ2 FY2027vs year agovs last quarter
Revenue$928.0M+17.6%+5.1%
Operating income$275.0M+40.4%+0.7%
Net income$273.4M+36.5%+4.8%
Diluted EPS$1.66+39.5%+5.7%
Gross margin75.0%−0.3 pts+0.0 pts
Operating margin29.6%+4.8 pts−1.3 pts

Calculated by code from XBRL, not by the model.

Guidance check

MetricOutlook given with Q1 FY2027ReportedResult
Revenue$902 and $905 million$928.0Mabove the range
EPS (non-GAAP)$2.21 and $2.22$2.35above the range

Compared with the company's own guidance, not analyst estimates, and only where the outlook and the reported figure are the same measure on the same basis. Ranges are worked out by code from the company's wording. How this works.

Outlook

MetricPeriodOutlook
Total revenuesfiscal third quarter ending October 31, 2026$932 and $935 million
Non-GAAP operating incomefiscal third quarter ending October 31, 2026$417 and $420 million
Non-GAAP diluted EPSfiscal third quarter ending October 31, 2026$2.33 and $2.34
Total revenuesfiscal year ending January 31, 2027$3,682 and $3,687 million
Non-GAAP operating incomefiscal year ending January 31, 2027~$1,640 million
Non-GAAP diluted EPSfiscal year ending January 31, 2027~$9.21
Non-GAAP operating cash flowfiscal year ending January 31, 2027~$1,600 million

Key takeaways

  1. Vault CRM momentum builds among largest biopharmas

    More than 180 customers are live, including five top 20 biopharmas, and two top 20 plus one large enterprise biopharma committed in August, bringing top 20 commitments to 12. This strengthens Veeva's position in its core commercial market.

  2. Agentic CRM is reaching full field deployment

    A top 20 biopharma deployed Vault CRM and the Agentic Call Report across its full U.S. field team in the quarter. It is a concrete example of AI moving into production use.

  3. Veeva Falcon targets clinical, regulatory and safety labor

    Falcon is described as an agentic labor platform with five early adopters and initial go-lives expected this year. Veeva also launched Veeva Falcon MLR to automate content reviews.

  4. Vault AI broadens with standard and custom agents

    August brought new standard agents, broader capabilities for existing agents, and advanced tools for building custom agents. This extends AI from Veeva's own agents to customer-built ones.

  5. R&D and Quality footprint keeps widening

    A large enterprise biopharma selected Veeva EDC on top of eTMF, CTMS and Study Startup, and Veeva Safety won its second top 20 biopharma for Safety Workbench. Quality added more than 30 new customers, with 20 or more wins each across QualityDocs, QMS and Training.

Charts

Revenue$928.0M+17.6% y/yQ2 FY27
Q3 FY25: $699.2MQ3 25$699.2MQ4 FY25: $720.9M (worked out from the annual figure)Q4 25$720.9MQ1 FY26: $759.0MQ1 26$759.0MQ2 FY26: $789.1MQ2 26$789.1MQ3 FY26: $811.2MQ3 26$811.2MQ4 FY26: $836.0M (worked out from the annual figure)Q4 26$836.0MQ1 FY27: $882.9MQ1 27$882.9MQ2 FY27: $928.0MQ2 27$928.0M

Fourth quarter worked out from the annual figure.

Data
Q3 FY25$699.2M
Q4 FY25$720.9M *
Q1 FY26$759.0M
Q2 FY26$789.1M
Q3 FY26$811.2M
Q4 FY26$836.0M *
Q1 FY27$882.9M
Q2 FY27$928.0M
Diluted EPS (GAAP)$1.66+39.5% y/yQ2 FY27
Q3 FY25: $1.13Q3 25$1.13Q1 FY26: $1.37Q1 26$1.37Q2 FY26: $1.19Q2 26$1.19Q3 FY26: $1.40Q3 26$1.40Q1 FY27: $1.57Q1 27$1.57Q2 FY27: $1.66Q2 27$1.66
Data
Q3 FY25$1.13
Q1 FY26$1.37
Q2 FY26$1.19
Q3 FY26$1.40
Q1 FY27$1.57
Q2 FY27$1.66

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin29.6%+4.8 pts y/yQ2 FY27
Q3 FY25: 25.9%Q3 2525.9%Q4 FY25: 26.1%Q4 2526.1%Q1 FY26: 30.8%Q1 2630.8%Q2 FY26: 24.8%Q2 2624.8%Q3 FY26: 29.7%Q3 2629.7%Q4 FY26: 29.4%Q4 2629.4%Q1 FY27: 30.9%Q1 2730.9%Q2 FY27: 29.6%Q2 2729.6%
Data
Q3 FY2525.9%
Q4 FY2526.1%
Q1 FY2630.8%
Q2 FY2624.8%
Q3 FY2629.7%
Q4 FY2629.4%
Q1 FY2730.9%
Q2 FY2729.6%

Questions

What were the main product developments at Veeva this quarter?

Veeva launched Veeva Falcon MLR, advanced Vault AI with new standard agents and custom agent tools, and acquired Copli. Veeva Falcon, its agentic platform for clinical, regulatory and safety, has five early adopters.

How is Vault CRM doing with large pharma customers?

More than 180 customers are live, including five top 20 biopharmas. Top 20 commitments reached 12 globally after two top 20 biopharmas and one large enterprise biopharma committed in August.

When will Veeva Falcon go live?

Veeva says Falcon is on track for initial go-lives this year, with five early adopters working with it now.

Is Veeva gaining ground in clinical, safety and quality software?

Yes, according to the release. A large biopharma selected Veeva EDC, Veeva Safety passed 100 customers with a second top 20 Safety Workbench win, and Quality added more than 30 new customers.

How is Veeva positioning itself around AI?

Veeva describes AI as the next big chapter and combines applications, agents, data and consulting for life sciences. Its AI offerings include Vault AI agents, the Agentic Call Report and Falcon agentic labor.